If you're taking finasteride for BPH or hair loss, or dutasteride for BPH, you've probably run across a claim somewhere that the drug "causes prostate cancer" or "increases high-grade prostate cancer." That claim traces back to two of the largest randomized prostate cancer prevention trials ever conducted — and the honest answer is more specific, and more reassuring, than either the scary headline or a flat "no risk at all."
Both trials found something that looked unsettling at first: fewer prostate cancers overall in the men taking the drug, but a higher share of the cancers that were found rated as high-grade. What took years of additional follow-up to resolve was why that signal showed up, and whether it actually mattered for survival. Here's what the data — not the forum threads — shows.
The PCPT: Finasteride Cut Overall Risk by About a Quarter
The Prostate Cancer Prevention Trial (PCPT) randomized 18,882 men age 55 and older with a normal digital rectal exam and a PSA of 3.0 ng/mL or lower to finasteride 5 mg daily or placebo for seven years, with biopsy recommended if adjusted PSA exceeded 4.0 ng/mL or the exam became abnormal. Prostate cancer was detected in 18.4% of men in the finasteride group versus 24.4% in the placebo group — a 24.8% relative reduction (95% CI, 18.6-30.6%; P<0.001) [1].
The complication: among the cancers that were found, a higher proportion were Gleason grade 7-10 (high-grade) in the finasteride group — 37.0% of finasteride-group tumors versus 22.2% of placebo-group tumors, or 6.4% versus 5.1% of all men in each group [1]. That's the finding behind the "finasteride causes aggressive prostate cancer" headlines. It's also only half the story.
Why the High-Grade Signal Needs Context
A follow-up PCPT analysis asked a more specific question: does finasteride change how well PSA actually works as a cancer-detection tool, independent of whether it changes cancer biology? The answer was yes, and in a way that explains much of the high-grade signal. PSA's area-under-the-curve (a measure of how well a test distinguishes cancer from no cancer) for detecting any prostate cancer was 0.757 in the finasteride group versus 0.681 in the placebo group (P<0.001); for detecting Gleason grade 7 or higher specifically, it was 0.838 versus 0.781 (P=0.003) [2].
In plain terms: PSA worked better as a detection tool in the finasteride group, and the researchers concluded that this bias "would be expected to contribute to greater detection of all grades of prostate cancer with finasteride" [2]. That is one reason more cancers, including high-grade ones, may have been found on biopsy in the finasteride arm. But the analysis does not show that the bias explains the whole high-grade difference, and the later 18-year report still found more high-grade cancer with finasteride [4]. That is why the long-term survival data below matters so much.
REDUCE: Dutasteride Showed Largely the Same Pattern
The REDUCE trial tested the same question for dutasteride, in a different population: 6,729 men age 50-75 with a PSA of 2.5-10.0 ng/mL and one prior negative biopsy, randomized to dutasteride 0.5 mg daily or placebo for 4 years, with repeat biopsies at years 2 and 4. Cancer was detected in 659 of 3,305 men on dutasteride versus 858 of 3,424 on placebo — a 22.8% relative risk reduction (95% CI, 15.2-29.8%; P<0.001) [3].
- •Across the full 4 years, there was no significant difference in Gleason 7-10 tumors between groups (220 with dutasteride vs. 233 with placebo, P=0.81)
- •But in years 3 and 4 specifically, Gleason 8-10 tumors were more common with dutasteride (12 cases) than placebo (1 case, P=0.003)
- •Dutasteride also reduced acute urinary retention by 77.3% relative to placebo (1.6% vs. 6.7%) — the BPH-related benefit the drug is actually prescribed for
| Trial | Drug & Dose | Population | Overall Cancer Risk Reduction | High-Grade Signal |
|---|---|---|---|---|
| PCPT (2003) | Finasteride, 5 mg/day | 18,882 men, age 55+, PSA ≤3.0 ng/mL, 7 years | 24.8% fewer cancers overall | Higher share of detected cancers were Gleason 7-10 |
| REDUCE (2010) | Dutasteride, 0.5 mg/day | 6,729 men, age 50-75, PSA 2.5-10.0 ng/mL, prior negative biopsy, 4 years | 22.8% fewer cancers overall | No difference in Gleason 7-10 overall; higher Gleason 8-10 specifically in years 3-4 |
The Question That Actually Matters: Did It Affect Survival?
PCPT participants were followed for up to 18 years, with survival status checked against the Social Security Death Index. With that longer follow-up, prostate cancer was eventually diagnosed in 10.5% of the finasteride group versus 14.9% of the placebo group (relative risk 0.70), and high-grade disease remained modestly more common with finasteride (3.5% vs. 3.0%; relative risk 1.17, 95% CI 1.00-1.37, P=0.05) [4].
Here's the part that actually settles the question: 15-year overall survival was 78.0% in the finasteride group versus 78.2% in the placebo group — statistically indistinguishable (hazard ratio for death 1.02, 95% CI 0.97-1.08, P=0.46). Broken down by cancer grade, 10-year survival for men with low-grade disease was 83.0% (finasteride) versus 80.9% (placebo), and for men with high-grade disease it was 73.0% versus 73.6% [4]. After nearly two decades of follow-up, the high-grade signal that generated so much concern in 2003 never translated into a measurable survival difference, in either direction.
What This Means If You're Already Taking Finasteride or Dutasteride
- •Don't stop a 5-ARI you're taking for BPH or hair loss based on this alone — talk to the prescriber who put you on it first
- •Your PSA reading needs reinterpretation on a 5-ARI: these drugs suppress PSA by roughly half, so a value that looks reassuringly low may not be — see PSA False Positives for how that adjustment actually works
- •Keep whatever PSA or biopsy monitoring schedule your urologist has set, rather than assuming the drug itself is doing the monitoring for you
- •If a biopsy while on a 5-ARI does find Gleason 7 or higher disease, the 18-year PCPT survival data for finasteride gave no indication it behaves more aggressively than the same finding would off the drug — it's evaluated and treated the same way
Does This Apply the Same Way at Hair-Loss Doses?
Not directly. PCPT studied finasteride at 5 mg/day — five times the 1 mg/day dose typically used for hair loss — in men age 55 and older selected partly for low baseline PSA, not the broader, often younger population taking 1mg finasteride for hair loss. The direction of the biology (lowering DHT, suppressing PSA) is the same at either dose, so the PSA-interpretation point still applies if you're ever screened for prostate cancer — but the specific risk-reduction and high-grade percentages from PCPT and REDUCE don't transfer 1:1 to a lower dose in a different population.
If you're on a 5-ARI for BPH, tracking how your urinary symptoms and any PSA results trend over months — rather than relying on memory at your next urology visit — makes it easier to have an informed conversation about what's actually changing.
Take This Data to Your Urologist
Don't try to explain a month of symptoms in a 10-minute appointment. ManCore Pro generates a clean, professionally formatted PDF — symptom charts, supplement log, and bladder diary — ready to hand to your doctor.
General Prostate & Urinary Support
Super Beta Prostate Supplement
A general prostate and urinary-support formula some men on finasteride or dutasteride for BPH add alongside their prescription — not a substitute for the drug itself, and worth mentioning to your urologist given the PSA-interpretation nuances above.
Male Optimization Formula
A broader men's-health formula covering multiple support pathways; useful as a general wellness baseline, though it doesn't replace the BPH symptom relief or PSA-monitoring routine a 5-ARI prescription involves.
NOW Foods Pumpkin Seed Oil
A widely used urinary-support supplement some men layer onto a 5-ARI regimen; check with your prescriber before adding any supplement, mainly so your care team has the full picture of what you're taking.
Affiliate disclosure: ManCore earns a small commission on purchases made through these links at no extra cost to you.
Frequently Asked Questions
Does finasteride cause prostate cancer?
In the main trial (the PCPT), men taking finasteride had 24.8% fewer prostate cancers overall than men on placebo, but a higher share of the cancers found were high-grade. A follow-up analysis found that PSA was a more sensitive detection tool in the finasteride group, which would be expected to contribute to finding more cancers of all grades. High-grade cancer was still somewhat more common with finasteride in the 18-year report (3.5% vs. 3.0%), and survival was not significantly different between the groups [4].
Should I stop taking finasteride or dutasteride because of this?
Not based on this evidence alone. Both drugs reduced overall prostate cancer incidence in their respective trials. For finasteride, the 18-year PCPT follow-up found no significant survival difference between the drug and placebo groups, including among men with high-grade disease; REDUCE followed men for only 4 years. Any decision to stop a 5-ARI should be made with the prescriber managing your BPH or hair loss treatment, not from a single statistic taken out of context.
Why does my doctor adjust my PSA number if I'm on finasteride or dutasteride?
Because these drugs suppress PSA by roughly 50% after 6-12 months of use, a raw PSA reading on a 5-ARI understates what your PSA would be off the drug. Most clinicians account for this when deciding whether a result warrants further workup — failing to adjust for it risks under-interpreting a result that actually needs attention.
Did REDUCE's dutasteride results differ meaningfully from PCPT's finasteride results?
Not in the broad pattern. Both trials found a similar magnitude of overall risk reduction (roughly 23-25%), and both found a high-grade signal — REDUCE's was concentrated specifically in years 3 and 4 of the study rather than spread evenly across the full period. Neither trial's design allows a direct head-to-head comparison between the two drugs, since they studied different populations and follow-up lengths.
Does this research apply to the lower dose used for hair loss?
The PSA-interpretation point applies regardless of dose, since finasteride still suppresses PSA at 1 mg/day. But PCPT studied 5 mg/day in men 55 and older selected for low baseline PSA, so its specific risk-reduction and high-grade percentages don't directly transfer to the typically younger, average-risk population using 1 mg finasteride for hair loss.
Related Articles
Finasteride vs. Dutasteride for BPH
How the two 5-alpha reductase inhibitors compare for treating enlarged prostate.
PSA False Positives
What raises PSA besides cancer, and how 5-ARIs factor into interpreting your number.
Prostate Cancer Treatment Options
Active surveillance, surgery, radiation, and hormone therapy compared by risk group.